VSTMVerastem, Inc.Running, no new patients
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Non Small Cell Lung Cancer · KRAS Activating Mutation
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Worry score12
Score over time
- Stage
- Phase 1/2
- Patients
- 153 (planned)
- Started
- Apr 12, 2022
- Main results expected
- Jun 2026
- Fully finished
- Apr 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib
Measured over: From start of treatment to confirmation of RP2D; 28 days
Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part A
Measured over: From start of treatment to confirmation of response; 16 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT05074810 · record last updated 2026-01-12 · checked 2026-11-09 15:42 UTC